LICENSING OPPORTUNITIES

Licensing Opportunities

The La Jolla Institute for Immunology is a world-renowned research organization specializing in human immunology and its role in human disease. Our 20+ principal investigators conduct groundbreaking, world changing research in all areas of immunology including oncology, cardiovascular disease, infectious diseases, allergy, inflammation, and autoimmunity. A number of their pioneering innovations are in clinical development. In addition, LJI is a leader in the worldwide effort for identification and bioinformatic characterization of antigens, including management of the Immune Epitope Database and the development of peptide pools used to diagnose viral infections and characterize immune response.

LJI and its researchers partner with companies in a variety of capacities, including as scientific advisors, through sponsored research collaborations and by licensing technologies. There are over 300 technologies available for licensing, some of which are listed below. LJI welcomes inquiries regarding licensing and other collaborative opportunities. Please contact us at bd@lji.org to get in touch with our business development group. We look forward to making introductions to investigators and exploring how we can work together.

HRF inhibitors
Researchers at the La Jolla Institute for Immunology (LJI) have developed rabbit monoclonal antibodies that recognize the HRF N19 peptide and are working to humanize these antibodies for therapeutic use. These mAbs were generated by screening a phage antibody library, and they inhibited IgE binding of HRF in vitro and in ovalbumin-induced food allergy in vivo.
READ MORE
HVEM Muteins
Researchers at the La Jolla Institute for Immunology and the Albert Einstein College of Medicine together have generated HVEM mutants that selectively recognize either the TNF ligand LIGHT or the Ig ligands BTLA and CD160 in vitro. Knock-in mice expressing these muteins maintain expression of all the proteins in the HVEM network yet demonstrate selective functions for LIGHT or BTLA/CD160.
READ MORE
Mpox Epitopes
Researchers in the Sette lab at the La Jolla Institute for Immunology (LJI) have compiled known epitope information to determine protein conservation and immunodominance for both CD4+ and CD8+ T cell responses to Mpox virus (MPXV). Additionally, the researchers have developed epitope pools that can be utilized to assess responses to vaccination and MPXV infection.
VFLIP
Researchers in the Saphire lab have developed a novel pre-fusion stabilized SARS-CoV-2 Spike (S) glycoprotein termed “VFLIP” for (V) five proline, Flexibly-Linked, Inter-Protomer spike.
Previous slide
Next slide

Available Technologies

Infectious Disease

A Novel Cytomegalovirus Cell-Entry Protein Complex

A Novel Cytomegalovirus Cell-Entry Protein Complex

Stabilized, Trimeric Rabies Virus Glycoprotein

Tonsillitis and Killer TFH Cells

Pan-Flavivirus Vaccine that Protects Against Zika Virus and Dengue Virus

Vaccine Design

Filovirus Immunogen Display Platform

Supertope Carrier

Ketol-Acid Reductoisomerase as a Novel Nanoparticle

Cancer

BATF and IRF4 Cooperate to Counter Exhaustion in Tumor-Infiltrating CAR-T Cells

HVEM Muteins for Cancer and Other Uses

 

Patrolling Monocytes Control Tumor Metastasis to the Lung

Rel-B-Depleted CAR T Cells

Novel Epitopes and Antigens

Bordetella pertussis T Cell Epitopes and Megapools

Monkeypox T Cell Epitopes and Megapools

Novel Cockroach Antigens and T Cell Epitopes

Antigens and Epitopes Derived from Mycobacterium tuberculosis

Dengue Virus Polypeptide Sequences and T Cell Epitopes

Peptides for Preventing and Treating Atherosclerosis

Timothy Grass Antigens and T CellEpitopes

Allergy, Inflammation, and Autoimmune Diseases

HRF Inhibitors for the Prevention of Food Allergy

Modulation of T Cell Signaling Via SLAT Association with IP3R1

Antigens and Epitopes Derived from Mycobacterium tuberculosis

COVID

SARS-CoV-2 Spike Glycoprotein with Improved Expression and Stability

NFKbid Overexpression Supports the Expansion and Survival of CD8+ Tumor-Infiltrating Lymphocytes

Anti-SARS-CoV-2 Nucleoprotein Antibodies

Anti-SARS-CoV-2 Spike Antibodies

Related News

LJI scientists discover new drug target for severe asthma, fibrosis

Contact